BPC-157 dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 8 published studies are one click away.
Small human studies Repair Also called Body Protection Compound 157
Common use ranges
From published clinic and pharmacy protocols. No drug label exists. Strong agreement on 250 to 500 mcg once or twice daily for 4 to 6 weeks. The injury tier is reported by fewer sources.
- Half-life
- under 30 minutes in rats and dogs (about 15 minutes in the rat vein, 8 to 30 minutes as a rat muscle shot)
- How it is taken
- Subcutaneous injection, often near the injured area or in the belly fat
- How long people use it
- Usually 4 to 6 weeks, up to 8 to 12 weeks for slow or chronic cases, then a 2 to 4 week break. One clinic runs 5 days on and 2 days off for a month.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 250 mcg | 5 units 0.05 mL | once a day | 250 mcg once a day for the first 1 to 2 weeks, then step up if it is going fine | about 6 weeks |
| Typical [2] | 250 mcg | 5 units 0.05 mL | 2x a day | 250 to 500 mcg a day in total, as one shot or split into two shots about 12 hours apart | 20 days |
| Injury (reported) [3] | 500 mcg | 10 units 0.10 mL | 2x a day | Up to 500 mcg twice a day (about 1 mg a day) for a short block on a fresh or severe injury, then back down | 10 days |
Good to know
- 250 to 500 mcg once or twice a day is the clear common range.
- About 1 mg a day (500 mcg twice daily) shows up only as the top of the range for severe or acute injury, and sources say it has less support.
- 2 mg a day does not appear in any clinic or pharmacy protocol.
- Some protocols inject close to the injury site. Others use the belly for gut or whole body use.
- One large clinic removed the doses from one of its BPC-157 pages in September 2026, saying no human dose-finding study exists.
Sources for these amounts
- Starting: Dr. Rogers Centers, BPC-157 Dosage Guide · Form Blends, BPC-157 Dosage Guide (conservative tier 200 to 250 mcg once daily) · Pure Peptide Clinic, BPC-157 Dosing (low dose 200 to 250 mcg a day)
- Typical: Pure Peptide Clinic, BPC-157 Dosing (standard 500 mcg a day, as 250 mcg twice daily or one 500 mcg shot) · Dr. Rogers Centers, BPC-157 Dosage Guide (250 to 500 mcg, 1 to 2 times daily) · Perfect B clinic, BPC-157 Dosage Protocol (250 to 500 mcg a day) · Form Blends, BPC-157 Dosage Guide (standard 250 to 500 mcg a day)
- Injury (reported): Pure Peptide Clinic, BPC-157 Dosing (acute injury 250 to 500 mcg twice daily, 750 to 1,000 mcg a day for severe injuries) · Dr. Rogers Centers, BPC-157 Dosage Guide (titrate up to 500 mcg twice daily, practitioners use up to 1,000 mcg a day) · Form Blends, BPC-157 Dosage Guide (acute injury and post-surgery 250 mcg twice daily, research maximum 500 to 800 mcg)
How long people use it: Dr. Rogers Centers · Pure Peptide Clinic · Perfect B clinic · Form Blends
Half-life: He et al 2022, Front Pharmacol, PK of BPC157 in rats and dogs
Take the BPC-157 chart with you
Get a one-page printable chart for BPC-157, with the syringe units for each vial and water mix. We can also email you when a new BPC-157 study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 8 published studies
Amounts given to people in studies
How it was given: One-time doses given by a doctor. IV drip (2 people) and one injection during a bladder procedure (12 women).
These are single doses, not daily amounts. No published study has given BPC-157 to people day after day. Both reports come from one clinic group, with no control group. An oral phase 1 trial planned 1 to 6 mg but never posted results.
Amounts given to animals in studies
Every study used for this page
Proof grade: Small human studies. Only small or uncontrolled human studies. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 40131143Lee & Burgess, Altern Ther Health Med 2025;31(5):20-24 | Human, 2 adults (58 M, 68 F) | 10 mg in 250 cc saline over 1 h (day 1), then 20 mg in 250 cc saline over 1 h (day 2) | IV infusion | One infusion per day, 2 doses | 3 days (bloods day 3) | No change in heart, liver, kidney, thyroid or glucose markers, no side effects. Both had prior IV BPC-157. n=2, no control |
| PMID 39325560Lee, Walker, Ayadi, Altern Ther Health Med 2024 | Human, 12 women (mean age 58.3), interstitial cystitis | Total 10 mg | Injected around bladder inflammation during cystoscopy | Single procedure | Single dose | 10/12 complete resolution, 2/12 80%. No adverse events. Open-label, no control. 503A compounded product |
| PMID 34324435Lee & Padgett, Altern Ther Health Med 2021 | Human, 17 pts charted (16 followed up) | Not stated in the abstract | Intra-articular knee (BPC alone n=12, with TB4 n=4) | Not stated | Follow-up 6-12 months | 11/12 BPC-alone and 3/4 combo improved. Retrospective chart review, phone survey. Dose could not be verified |
| NCT02637284ClinicalTrials.gov, not PubMedStart 2015-10 | Human phase I, planned n=42 | "Bepecin" oral tablets of 1 mg: single dose of 1, 3 or 6 tablets (1, 3, 6 mg, 12 subjects per cohort), then 3 tablets (3 mg) every 8 h for 2 weeks (36 active, 6 placebo) | Oral tablet | Single dose, then every 8 h | 2 weeks (multiple-dose arm) | STATUS: UNKNOWN (last known ACTIVE_NOT_RECRUITING, record last updated 2015-12, est. completion 2016-03). No results posted. No publication found |
| PMID 20225319Cerovecki et al., J Orthop Res 2010 | Rat (n not in abstract), MCL transection | 10 mcg/kg or 10 ng/kg IP. Topical 1.0 mcg per g neutral cream. Oral 0.16 mcg/ml in drinking water, 12 ml/day/rat | IP, topical cream, drinking water | Once daily, first dose 30 min after surgery | Up to 90 days | Improved function, biomechanics, histology at both IP doses |
| PMID 16583442Achilles detachment, J Orthop Res 2006 | Rat (n not in abstract) | 10 mcg/kg, 10 ng/kg, 10 pg/kg | IP | Once daily, first 30 min after surgery, last 24 h before analysis | Days 1 to 21 | Improved function, biomechanics, histology. Lowest dose found (10 pg/kg) |
| PMID 16609979quadriceps transection, J Orthop Res 2006 | Rat (n not in abstract) | 10 mcg, 10 ng, 10 pg per kg | IP | Once daily, first 30 min after transection | 72 days | Improved biomechanics, function, histology |
| PMID 36588717He et al., Front Pharmacol 2022, PK | Rat (n=6 per group per PMC text) and beagle dog | Abstract gives no numbers ("three doses" IM). Dog IV 6 mcg/kg, IM 6, 30, 150 mcg/kg, repeat 30 mcg/kg x7 d | IV and IM | Single, or daily x7 | 7 days | t1/2 under 30 min. IM bioavailability ~14-19% rat, 45-51% dog. Highest per-kg dose found: 500 mcg/kg rat IM. Authors' proposed human dose 200 mcg/person/day (full text) |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of BPC-157 were used in human studies?
In the studies listed here, people were given from 10 mg, one time only (injected into the bladder wall, 12 women) up to 20 mg, one time only (IV drip, same 2 people, the next day). The amount used most often was 10 mg, one time only (IV drip, 2 people). These are what study teams chose for their participants under supervision.
Where do these BPC-157 numbers come from?
From 8 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Small human studies.
How long does BPC-157 stay in the body?
Its half-life is under 30 minutes in rats and dogs (about 15 minutes in the rat vein, 8 to 30 minutes as a rat muscle shot), measured in animals, not people. Half-life is how long it takes for half of a dose to leave the blood. The effect can last longer than that.
Is this a recommendation for how much BPC-157 to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.